Cell processing labs face an array of new and sometimes contradictory challenges, e.g., finding ways to increase quality while decreasing costs, and ensuring better product/patient outcomes despite increasing patient volume.

On-Premise software is just as it sounds: software installed locally and run on the organization’s computers and servers. The associated software as well as the clinical data entered is stored locally on in-house servers, it never leaves the premises.

An essential component of allogeneic and autologous hematopoietic cell transplantation (HCT) is the conditioning regimen administered before the hematopoietic cell infusion. Intended to allow engraftment of donor cells and/or control a malignant disease, conditioning regimens – typically based on national protocols and cutting-edge studies – play an important role in the long-term outcome of HCT.

Physicians and clinicians need ways to paint a picture of transplant data in order to interpret it. Too often, however, care teams are using inefficient means of working with data, such as spreadsheets.

Communication flows forward, backwards and sideways in all organizations, including cell therapy and solid organ transplant centers. The benefits of effective interdisciplinary communication include improved patient outcomes, increased patient satisfaction (poor communication among providers can negatively impact a patient’s perception of care delivery), and increased healthcare savings (less wasted time).

EDITLife, the Transplant Management System vendor with the most advanced technologies, knows the challenges that implementation can present and how to mitigate them. Using EDITLife tools and processes, even the most complex implementation can realize success and return on investment in a reasonable amount of time.

Data silos often emerge in hospitals because each department has different goals, priorities, and responsibilities – and separate databases. Siloed systems curb efficiency and stifle collaboration, as well as increase the likelihood of miscommunications and critical information not reaching those who need it most.

Determining whether to move forward with licensing a new cell therapy data and clinical workflow management system is a decision that should only be made after knowing all the facts.

CAR-T (T-cells expressing Chimeric Antigen Receptors) therapy has displayed significant success in treating patients with otherwise incurable B-cell lymphomas. The field is rapidly expanding to include new disease indications and CAR designs.